These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 22811549)

  • 1. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging.
    Olivotto I; Cecchi F; Poggesi C; Yacoub MH
    Circ Heart Fail; 2012 Jul; 5(4):535-46. PubMed ID: 22811549
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk stratification in hypertrophic cardiomyopathy: time for renewal?
    Pacileo G; Salerno G; Gravino R; Calabrò R; Elliott PM
    J Cardiovasc Med (Hagerstown); 2013 May; 14(5):319-25. PubMed ID: 22885536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative exercise-induced left ventricular systolic and diastolic dysfunction in hypertrophic cardiomyopathy.
    Pelliccia F; Cianfrocca C; Pristipino C; Pasceri V; Auriti A; Richichi G; Mangieri E; Gaudio C
    Int J Cardiol; 2007 Oct; 122(1):76-8. PubMed ID: 17196685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of cardiac fibrosis is the largest unmet medical need in heart failure.
    Díez J; de Boer RA
    Cardiovasc Res; 2022 Jan; 118(2):e20-e22. PubMed ID: 34244741
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hypertrophic cardiomyopathy: course characteristics in long-term follow-up].
    Belenkov IuN; Privalova EV; Kaplunova VIu; Fomin AA
    Ter Arkh; 2008; 80(8):18-25. PubMed ID: 18807535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in heart failure imaging.
    Marwick TH; Raman SV; Carrió I; Bax JJ
    JACC Cardiovasc Imaging; 2010 Apr; 3(4):429-39. PubMed ID: 20394905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'End-stage' hypertrophic cardiomyopathy: from mystery to model.
    Yacoub MH; Olivotto I; Cecchi F
    Nat Clin Pract Cardiovasc Med; 2007 May; 4(5):232-3. PubMed ID: 17457348
    [No Abstract]   [Full Text] [Related]  

  • 8. High throughput phenotyping of left and right ventricular cardiomyopathy in calcineurin transgene mice.
    Moreth K; Afonso LC; Fuchs H; Gailus-Durner V; Katus HA; Bekeredjian R; Lehman L; Hrabě de Angelis M
    Int J Cardiovasc Imaging; 2015 Apr; 31(4):669-79. PubMed ID: 25627778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution and clinical importance of fibrosis in HCM.
    Quarta G; Grasso A; Pasquale F; Flett AS; Sado DM; Bonini E; Ariti C; Prasad SK; Elliott PM; Moon JC
    JACC Cardiovasc Imaging; 2011 Nov; 4(11):1221-3. PubMed ID: 22093275
    [No Abstract]   [Full Text] [Related]  

  • 10. MRI of hypertrophic cardiomyopathy: part 2, Differential diagnosis, risk stratification, and posttreatment MRI appearances.
    Hansen MW; Merchant N
    AJR Am J Roentgenol; 2007 Dec; 189(6):1344-52. PubMed ID: 18029870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis as a possible cause of wall thinning in end-stage hypertrophic cardiomyopathy.
    Ino T; Nishimoto K; Okubo M; Akimoto K; Yabuta K; Kawai S; Okada R; Sueyoshi N
    Am J Cardiol; 1997 Apr; 79(8):1137-41. PubMed ID: 9114784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac resynchronization: what's next?
    Leclercq C
    Arch Cardiovasc Dis; 2012; 105(6-7):335-7. PubMed ID: 22800717
    [No Abstract]   [Full Text] [Related]  

  • 13. Isolated left ventricular non-compaction: an unusual indication for heart transplantation.
    Fan KY; Chan CW; Cheng LC; Ko RL; Lam YM; Jim MH; Au TW; Ho CK; Wang EP; Chau EM; Chow WH
    Hong Kong Med J; 2009 Oct; 15(5):378-80. PubMed ID: 19801696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.
    Maron MS; Appelbaum E; Harrigan CJ; Buros J; Gibson CM; Hanna C; Lesser JR; Udelson JE; Manning WJ; Maron BJ
    Circ Heart Fail; 2008 Sep; 1(3):184-91. PubMed ID: 19808288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Many Faces of Fabry's Cardiomyopathy.
    Jain R; Kalvin L; Johnson B; Muthukumar L; Khandheria BK; Tajik AJ
    JACC Cardiovasc Imaging; 2018 Apr; 11(4):644-647. PubMed ID: 29361493
    [No Abstract]   [Full Text] [Related]  

  • 16. "Underestimation" of a left ventricular threshold.
    Ploux S; Thambo JB; Bordachar P
    Arch Cardiovasc Dis; 2011 Nov; 104(11):591-2. PubMed ID: 22117912
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypertrophic cardiomyopathy in childhood.
    Maron BJ
    Pediatr Clin North Am; 2004 Oct; 51(5):1305-46. PubMed ID: 15331286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restrictive myocardium with an unusual pattern of apical hypertrophic cardiomyopathy.
    Sato T; Matsuyama TA; Seguchi O; Murata Y; Sunami H; Yanase M; Fujita T; Ishibashi-Ueda H; Nakatani T
    Cardiovasc Pathol; 2015; 24(4):254-7. PubMed ID: 25804825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac magnetic resonance predicts reversibility of cocaine-induced ventricular dysfunction.
    Smedema JP
    Cardiovasc J Afr; 2009; 20(3):198-9. PubMed ID: 19575088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A patient with hypertrophic obstructive cardiomyopathy presenting with left ventricular apical ballooning syndrome.
    Jaber WA; Wright SR; Murphy J
    J Invasive Cardiol; 2006 Oct; 18(10):510-2. PubMed ID: 17015918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.